Ozempic
Every GLP-1 the FDA has approved, and the active ingredient inside each one.
What is Ozempic?
Semaglutide sold as a weekly injection for type 2 diabetes at 0.5, 1 and 2 mg, and now also as a daily tablet at 1.5, 4 and 9 mg (Ozempic tablets, which replace Rybelsus).
For people with type 2 diabetes, the injection is also approved to lower the odds of a heart attack, stroke or cardiovascular death once heart disease is established, and to slow kidney decline when chronic kidney disease is present. Chemically identical to Wegovy, approved for a different job, and prescribed off-label for weight loss constantly. The brand name turns up in advertising far more often than in the vial.
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where Ozempic comes up on this site
On GLP Watchdog, Ozempic comes up in 115 research articles, 79 seller reviews, 13 FDA warning letters and 4 tools. Browse the FDA warning letters.
Research that discusses it
- Blurred Vision on Ozempic or Mounjaro: Causes, How Long It Lasts, When It's Urgent
- Does Medicaid Cover Ozempic and Wegovy? Same Molecule, Different Answers
- Does Ozempic Cause Erectile Dysfunction? What the Evidence Shows
- How Long Can Zepbound, Wegovy and Ozempic Be Out of the Fridge?
- Phentermine vs Ozempic, Wegovy and Zepbound: Is Phentermine a GLP-1?
- Stopping Ozempic or Wegovy: Side Effects, Weight Regain and Keeping It Off
- All 115 articles are on the research page
Drug pages
Tools that use it
Seller reviews that mention it
Other terms under Drugs and brands
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers